Celcuity Seizes Momentum with Groundbreaking Q1 Results
Celcuity, a leading biotechnology company, has marked a significant milestone in its journey towards revolutionizing the treatment of advanced breast cancer. The company's recent quarterly financial results and business update have revealed a plethora of exciting developments that are poised to take the industry by storm.
At the forefront of these advancements is the company's flagship drug candidate, gedatolisib, which has emerged as a potential game-changer in the fight against this devastating disease. The groundbreaking data reported from the wild-type cohort and the recent announcement of positive results from the mutant cohort of the VIKTORIA-1 study have solidified gedatolisib's position as a new standard of care for second-line therapy in patients with HR-positive, HER2-negative advanced breast cancer.
The past few months have been particularly eventful for Celcuity, with the company reporting positive top-line results for the PIK3CA mutant cohort of the phase III VIKTORIA-1 clinical trial. These findings are set to be presented in a late-breaking abstract oral session at the 2026 ASCO meeting on June 2nd, where they will undoubtedly garner significant attention from the scientific community.
Furthermore, Celcuity has announced two important updates to its clinical development plan. The expansion of the phase III VIKTORIA-2 trial to include a second study evaluating gedatolisib as first-line treatment in patients with endocrine-sensitive HR-positive, HER2-negative advanced breast cancer is a significant step forward. This will enable the company to evaluate nearly all patients in the first-line setting, irrespective of their endocrine sensitivity or PIK3CA status, thereby offering the potential to advance the standard of care for approximately 90,000 women each year who are newly diagnosed with HR-positive, HER2-negative advanced breast cancer in the U.S.
Additionally, Celcuity has announced its advancement of the development of a gedatolisib formulation for subcutaneous injection. This move is aimed at supporting potential future indications for gedatolisib regimens that may result in duration of treatment periods greater than several years. The company has also submitted its first patent application to the United States Patent and Trademark Office, further solidifying its commitment to this novel approach.
As Celcuity continues to push the boundaries of innovation, the company remains optimistic about the outcome of the FDA's review of its NDA. Assuming approval, a supplemental new drug application will be submitted based on the results of the PIK3CA mutant cohort VIKTORIA-1 and VIKTORIA-1 data for both the mutant and wild-type cohorts to other global regulatory authorities following the sNDA submission.
The top-line results from the PIK3CA mutant cohort have demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to alpelisib, a PI3K alpha inhibitor, and fulvestrant. These findings are a testament to Celcuity's unwavering dedication to developing effective treatments for advanced breast cancer.
